Articles Archives - Page 129 of 717

MondayOct 30, 2023 9:00 am

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer’s disease, met the primary endpoint of safety on statistical and medical assessment Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety was met based on statistical and medical assessment, with only one Serious Adverse…

FridayOct 27, 2023 9:45 am

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

PaxMedica Chairman and CEO Howard Weisman participated in a recent Bell2Bell Podcast interview and was joined by Buzz Woods from Corporate Communications Weisman discussed the company’s strategy to seek FDA approval for Suramin as a treatment for Human African Trypanosomiasis (“HAT”) and plans for 2024 If PaxMedica is successful in getting approval in HAT, the company believes that could lead to the receipt of a Priority Review Voucher (“PRV”) The company hopes to monetize the PRV to raise funds that will support research and future trials investigating Suramin as a treatment for Autism Spectrum Disorder PaxMedica hopes to file an…

FridayOct 27, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event

Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies Scinai will also exhibit at the upcoming BIO-Europe conference in Munich Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products,…

ThursdayOct 26, 2023 2:30 pm

GolfLync Inc. Unveils Exciting Updates to Enhance Your Golfing Experience

GolfLync, the leading social networking platform for golfers, is thrilled to announce a major update to its app, bringing a host of new features members will enjoy! Travel Mode: Play Golf Anywhere, AnytimeGolf and travel often go hand in hand, and GolfLync recognizes this synergy. The new Travel Mode allows members to change their location and seamlessly plan games, discover clubs, and connect with players in the area they are traveling to. Whether you're on a business trip, vacation, or simply exploring new golf courses, GolfLync makes it easy to find games and like-minded golfers across the country. With Travel…

ThursdayOct 26, 2023 9:45 am

DGE 4th Next Generation MSL Excellence Summit 2023: Navigating Thought Leader Engagement in the Digital Age

DGE’S 4th Next Generation MSL Excellence Summit will be held on November 13-14, 2023 in Philadelphia, along with a live streaming option. The event revolves around offering lucrative thought leader engagement strategies to MSLs and field executives along with data, tools, and tips to engage with their audiences. As remote meetings have become the preferred means of connection and communication post-covid, strategies need to be reshaped to meet the present challenges. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs…

ThursdayOct 26, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors

Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the highest commercial potential The company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio and is also filing new patent applications for discoveries that arise from its…

WednesdayOct 25, 2023 9:45 am

DGE 3rd Investigator Initiated Trials Summit 2023: Unlocking Innovations in Pharma Research and Collaboration

The 3rd Investigator Initiated Trials Summit will be held on November 13-14, 2023 in Philadelphia. The DGE event is focused on exploring the most lucrative ways for reviewing, selecting, and funding research investigators. Researchers, medical officers, health and pharma executives and companies can harness the reach and network of the DGE platform to connect with industry stalwarts and discuss vital issues on how they effectively manage IITs. The speakers will offer important insights on ways to leverage the new methods for new indications, label expansion and potential publications. The conference aims to create a bridge between pharma suppliers and sponsors…

WednesdayOct 25, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS

Clene's wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”) The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8 Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on…

TuesdayOct 24, 2023 9:45 am

Electronic Servitor Publication Network Inc.’s (XESP) Focused Approach to Creating Profitable Customer Interactions

XESP, a market disruptor for B2B companies, is offering businesses a way to create digital customer interactions that pay off Powered by its Digital Engagement Engine(TM), XESP is helping businesses avoid wastefulness while also achieving growth through its four-pronged approach With its proprietary smart tools and technologies, the company offers value to its clients, allowing them to reach their customers at the right moment- when they need the client’s product or service XESP is completely focused on the global customer engagement solutions market, projected to hit $32.2 billion in revenue by 2027, while also asserting itself as a leader in…

TuesdayOct 24, 2023 9:00 am

Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Provides Update on Drill Program; Announces Low-Dilutive Capital Raise

Prospera Energy recently provided an update on the second phase of the company’s restructuring plan With its initial five horizontal wells and incremental crude production tracking ahead of expectations, Prospera have announced plans to continue their second phase beyond its initially mooted ten well program The company has now announced that it will proceed with a low dilutive capital raise of $3 million, with proceeds destined to fund the exploration company’s ongoing capex Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western…

Site Search

Company Search

Category: Articles